NO20085290L - Metode - Google Patents

Metode

Info

Publication number
NO20085290L
NO20085290L NO20085290A NO20085290A NO20085290L NO 20085290 L NO20085290 L NO 20085290L NO 20085290 A NO20085290 A NO 20085290A NO 20085290 A NO20085290 A NO 20085290A NO 20085290 L NO20085290 L NO 20085290L
Authority
NO
Norway
Prior art keywords
mage
relates
probes
methods
specific
Prior art date
Application number
NO20085290A
Other languages
English (en)
Norwegian (no)
Inventor
Thierry Coche
Gabriele Annemarie Beer
Olivier Gruselle
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20085290L publication Critical patent/NO20085290L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20085290A 2006-06-21 2008-12-18 Metode NO20085290L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
NO20085290L true NO20085290L (no) 2009-01-19

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085290A NO20085290L (no) 2006-06-21 2008-12-18 Metode

Country Status (27)

Country Link
US (1) US8936919B2 (https=)
EP (1) EP2041308B1 (https=)
JP (2) JP2009540812A (https=)
KR (1) KR101455589B1 (https=)
CN (1) CN101506383B (https=)
AU (1) AU2007263019B2 (https=)
BR (1) BRPI0713599A2 (https=)
CA (1) CA2656909A1 (https=)
CO (1) CO6140072A2 (https=)
CY (1) CY1113290T1 (https=)
DK (1) DK2041308T3 (https=)
EA (1) EA016347B1 (https=)
ES (1) ES2389513T3 (https=)
GB (1) GB0612342D0 (https=)
HR (1) HRP20120761T1 (https=)
IL (1) IL195975A (https=)
MA (1) MA30565B1 (https=)
MX (1) MX2008016493A (https=)
MY (1) MY147511A (https=)
NO (1) NO20085290L (https=)
NZ (1) NZ573809A (https=)
PL (1) PL2041308T3 (https=)
PT (1) PT2041308E (https=)
SI (1) SI2041308T1 (https=)
UA (1) UA95956C2 (https=)
WO (1) WO2007147876A2 (https=)
ZA (1) ZA200810695B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699853A1 (en) 2007-09-17 2009-03-26 Oncomethylome Sciences Sa Improved detection of mage-a expression
BR112013001637A2 (pt) * 2010-07-22 2016-05-24 Glaxosmithkline Biolog Sa proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina.
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
WO1995023874A1 (en) * 1994-03-01 1995-09-08 Ludwig Institute For Cancer Research Determination of cancerous conditions by mage gene expression
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
PT1053325E (pt) * 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
RU2313365C2 (ru) 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
EP2363500A1 (en) * 2002-11-14 2011-09-07 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative RT-PCR
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
JP2009540812A (ja) 2009-11-26
DK2041308T3 (da) 2012-10-08
EA200802356A1 (ru) 2009-06-30
CO6140072A2 (es) 2010-03-19
JP2013046630A (ja) 2013-03-07
PL2041308T3 (pl) 2012-11-30
JP5705191B2 (ja) 2015-04-22
IL195975A0 (en) 2009-09-01
MY147511A (en) 2012-12-31
HK1127627A1 (en) 2009-10-02
EP2041308B1 (en) 2012-07-11
CY1113290T1 (el) 2016-04-13
US8936919B2 (en) 2015-01-20
AU2007263019B2 (en) 2012-11-08
IL195975A (en) 2012-08-30
HRP20120761T1 (hr) 2012-10-31
NZ573809A (en) 2011-12-22
MX2008016493A (es) 2009-05-21
GB0612342D0 (en) 2006-08-02
BRPI0713599A2 (pt) 2012-11-06
US20120040341A1 (en) 2012-02-16
AU2007263019A1 (en) 2007-12-27
CN101506383B (zh) 2013-08-28
KR20090034900A (ko) 2009-04-08
CA2656909A1 (en) 2007-12-27
EA016347B1 (ru) 2012-04-30
KR101455589B1 (ko) 2014-10-28
ZA200810695B (en) 2014-03-26
WO2007147876A3 (en) 2008-05-15
UA95956C2 (uk) 2011-09-26
CN101506383A (zh) 2009-08-12
EP2041308A2 (en) 2009-04-01
SI2041308T1 (sl) 2012-10-30
ES2389513T3 (es) 2012-10-26
WO2007147876A2 (en) 2007-12-27
PT2041308E (pt) 2012-10-09
MA30565B1 (fr) 2009-07-01

Similar Documents

Publication Publication Date Title
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
NO20084546L (no) Diagnostikk og behandlinger for tumorer
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
TW200740844A (en) Novel MAdCAM antibodies
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2007141280A3 (en) Proteins
WO2011073215A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application